휴온스글로벌 로고

Huonslab Advances in Human Hyaluronidase Development

- The drug diffusivity has been confirmed to be equivalent to that of the original-

- The goal is to release natural human hyaluronidase alone, and develop a drug diffusion agent for subcutaneous injection, instead of intravenous injection

Huonslab, a subsidiary of Huons Global, has taken a step closer in the development of hyaluronidase products.

On the 21st, Huonslab announced that it has confirmed that it’s ‘HLB3-002’ (API: Recombinant human hyaluronidase), exhibited a similar drug diffusing effect to a subcutaneous antibody drug containing Halozyme`s hyaluronidase enzyme, when tested at the same concentration.

The test was conducted through a CRO(Clinical Research Organization), which confirmed that the addition of HLB3-002 to the intravenous drug resulted in faster diffusion compared to administering the intravenous drug subcutaneously alone. Furthermore, in comparison with a subcutaneous drug containing hyaluronidase enzyme that was manufactured under the same conditions, HLB3-002 showed a similar drug diffusion effect and was confirmed to have equivalent efficacy to Halozyme`s hyaluronidase enzyme.

Hyaluronidase is used as a drug diffusion agent that directly decomposes hyaluronic acid in the subcutaneous tissue of the human body, pain relief and swelling. It is also used to convert intravenous injection drugs into subcutaneous injection products.

The global market for hyaluronidase drugs is expected to reach $1.4 billion in 2026 from $700 million in 2018 showing a high average annual growth rate of 8.6%.

HLB3-002 is a safe and highly productive recombinant human-sequence hyaluronidase in animal cell culture that has been purified with high purity. It has shown high activity and does not cause an immune response, even at high concentrations. Huonslab has verified that the efficacy of their HLB3-002 product is equivalent to that of Halozyme`s hyaluronidase enzyme, This enzyme can convert intravenous injection to subcutaneous injections.

Lim Chae-young, the executive director of Huonslab Bio Institute, announced, "As positive results were confirmed through the antibody drug diffusivity and pharmacokinetic test of HLB3-002 produced by animal cell culture technology, we are currently conducting non-clinical toxicity tests. And we will quickly prepare for clinical tests and release the human-derived natural hyaluronidase as a stand-alone product."

And he added, "As a stand-alone product, it will be used in the areas of plastic surgery, skin swelling and pain relief, HLB3-002 can convert biopharmaceutical intravenous injection into subcutaneous drugs, which can provide improved convenience.

Huonslab, a subsidiary of Huons Global, is a company that develops new biologics and biosimilars and is the third company in Korea to develop Prolia biosimilar on its own.